Provided by Tiger Trade Technology Pte. Ltd.

SIHUAN PHARM

1.200
-0.020-1.64%
Volume:50.29M
Turnover:59.80M
Market Cap:10.98B
PE:60.91
High:1.230
Open:1.230
Low:1.170
Close:1.220
52wk High:1.920
52wk Low:0.646
Shares:9.15B
HK Float Shares:9.15B
Volume Ratio:2.35
T/O Rate:0.55%
Dividend:0.02
Dividend Rate:1.87%
EPS(LYR):0.020
ROE:3.13%
ROA:2.69%
PB:1.63
PE(LYR):60.91
PS:3.64

Loading ...

Sihuan Pharmaceutical Proposes 2026 Share Incentive Scheme to Replace Existing Option Plan

Bulletin Express
·
May 08

SIHUAN PHARM (00460) Proposes Adoption of 2026 Share Incentive Scheme

Stock News
·
May 08

Sihuan Pharmaceutical proposes adopting 2026 share incentive scheme to replace option plan

Reuters
·
May 08

There May Be Underlying Issues With The Quality Of Sihuan Pharmaceutical Holdings Group's (HKG:460) Earnings

Simply Wall St.
·
May 06

Sihuan Pharmaceutical Reports No Share Capital Changes for April; Public Float Remains Compliant

Bulletin Express
·
May 04

四环医药控股集团2025年业绩回顾:营收同比增长37.7%,成功实现扭亏为盈

Bulletin Express
·
Apr 27

SIHUAN PHARM Publishes FY2025 Annual Report and ESG Report

Bulletin Express
·
Apr 27

SIHUAN PHARM (00460) Trustee Acquires 3 Million Shares Under Incentive Scheme

Stock News
·
Apr 21

Sihuan Pharmaceutical share award scheme trustee buys 3,000,000 shares at HK$1.36 average

Reuters
·
Apr 21

SIHUAN PHARM Shares Climb Nearly 3% as Subsidiary XUANZHUBIO-B Presents Promising Data on Diraoc in First-Line NSCLC Treatment at AACR

Stock News
·
Apr 21

Xuanzhu says Phase 1b NG-350A plus chemoradiotherapy hits 50% composite response rate

Reuters
·
Apr 20

Sihuan Pharma - Dirozalkib Shows Significant Efficacy Advantages in First-Line Alk-Positive Advanced Nsclc

THOMSON REUTERS
·
Apr 20

Sihuan Pharma - Xuanzhu Biopharm Presents Phase Iii Dirozalkib Data for Alk-Positive Nsclc at 2026 Aacr

THOMSON REUTERS
·
Apr 20

Xuanzhu says Phase III trial shows dirozalkib cuts lung cancer progression risk 53%

Reuters
·
Apr 19

Xuanzhu Biopharma wins HKEX approval to list 357,245,794 converted H shares

Reuters
·
Apr 17

Sihuan Pharm’s Xuanzhu Biopharm Secures CDE Approval for Phase III Trial of Anaprazole Sodium in Helicobacter Pylori Eradication

Bulletin Express
·
Apr 15

BUZZ-Xuanzhu Biopharmaceutical climbs to three-week high on approval for drug clinical trial

Reuters
·
Apr 15

Xuanzhu Biopharma wins China CDE nod for Phase III Anaprazole H. pylori trial

Reuters
·
Apr 15

BUZZ-China's Xuanzhu set for best day in 6 months on drug deal with Boston Oncology

Reuters
·
Apr 10

SIHUAN PHARM Subsidiary Xuanzhu Biopharm Inks >US$100 Million Licensing & Supply Deal with Boston Oncology for Breast and Lung Cancer Drugs in MENA

Bulletin Express
·
Apr 09